New Single-Use Fermentor Brings Microbial Applications Up to Speed
A new single-use fermentor matches the performance of stainless steel while eliminating clean/steam-in-place steps, reducing set-up time and mitigating cross-contamination risk in microbial fermentation.
The Thermo Scientific HyPerforma Single-Use Fermentor (SUF) is the first single-use system specifically engineered for microbial fermentation and designed to scale up from the lab to GMP production. Capable of meeting the aggressive performance demands of industrial microbiology, the HyPerforma SUF integrates into existing Thermo Scientific single-use technologies to achieve exceptional efficiency and scalability across the entire bioprocessing workflow.
Thermo Fisher will showcase its new HyPerforma Single-Use Fermentor this week at the BioProcess International Conference and Exhibition, 21–23 October 2014 at the Hynes Convention Center, Booth #301.
“Until now, fermentation equipment has been hard to convert to single-use due to the aggressive demands of fast-growing microbial cultures. Modified single-use bioreactors have been used, but are not designed for ideal growth conditions,” said Daniel Nelson, product manager, single-use systems at Thermo Fisher Scientific. “Through engineering an innovative, single-use exhaust and condenser system, coupled with powerful mixing, we overcame constraints in oxygen transfer to create the first purpose-built single-use fermentor. The HyPerforma SUF is a natural progression developed specifically for fermentation processes and a dedicated tool needed to increase choice, flexibility and performance for all bioprocessing workflows.”
Key product features include:
• Effective mass transfer, powerful mixing, and temperature control using three Rushton-style impellers and baffled, jacketed vessel
• 5:1 turndown ratio and 3:1 height-to-diameter ratio for consistent scalability and flexibility of process design (both 30 L and 300 L models).
• Efficient exhaust management system, enabling high flow rates (2VVM)
• Vertical access door for easy loading and retrieval of the bioprocess containers and harvest lines.
• Turn-around times between batches as low as 2 hours.
As a two-part product, the HyPerforma SUF comes paired with a Thermo Scientific BioProcess Container (BPC) — pre-sterilised and gamma irradiated. With an open architecture design, the HyPerforma SUF with BPC is highly flexible. It can also be retrofitted into existing fermentor operations, as well as configured to operate with existing software and control equipment, or delivered turnkey for immediate use.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.